RxDoctor Payments Data

Tahoora Kawaja, MD

Internal Medicine · Owings Mills, MDNPI 1568574663

Payments from drug & device makers

$905in general payments, 2019–2025

Across 49 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$221
  • Boehringer Ingelheim$114
  • AbbVie$92
  • Novo Nordisk$88
  • Exact Sciences$67
  • AstraZeneca$65
  • plus $258 from 7 others

What the payments were for

  • Food & beverage$905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC12$221
Boehringer Ingelheim7$114
AbbVie4$92
Novo Nordisk6$88
Exact Sciences3$67
AstraZeneca4$65
Amgen(2 entities)2$50
Abbott3$50
Merck3$49
Amarin Pharma, Inc.2$41
Johnson & Johnson1$31
Mylan Institutional Inc.1$23
Novartis1$15

How this compares

$905 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$61,814
Medicare patients
190
Services billed
670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$63,274
JanuviaSitagliptin Phosphate54$42,736
EliquisApixaban37$42,328
TrulicityDulaglutide18$24,947
MounjaroTirzepatide24$24,240
OzempicSemaglutide16$16,283
XareltoRivaroxaban19$12,218
Tresiba Flextouch U-200Insulin Degludec12$6,557
VascepaIcosapent Ethyl14$4,962
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,172
Ezetimibe13$3,024
Potassium Chloride86$2,918
Amlodipine Besylate282$2,793
Atorvastatin Calcium188$2,686
Rosuvastatin Calcium78$2,320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$114$63,27450 claims
Lilly USA, LLCTrulicity, Mounjaro$221$49,18742 claims
MerckJanuvia$49$42,73654 claims
Novo NordiskOzempic$88$16,28316 claims
Johnson & JohnsonXarelto$31$12,21819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Owings Mills

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →